A substantial portion of children with infantile spasms do not respond to first-line treatment, and Eton Pharmaceuticals is betting that an established growth-failure drug can reach them. The company’s November 2 SEC filing describes ET-900, a new program testing mecasermin injection in children with refractory epileptic spasms, with first patient dosing targeted for the first quarter of 2027.
The scientific rationale comes from Baylor College of Medicine, which licensed patent rights covering IGF-1’s role in spasms to Eton. The scientific rationale underlying the license involves IGF-1’s role in spasms, though the filing does not detail the specific research findings that support it. Mecasermin itself is not a new molecule: the FDA approved it in 2005 as Increlex for growth failure in children with severe IGF-1 deficiency, which gives Eton a known safety and formulation baseline to work from rather than starting from scratch.
The immediate regulatory step is a research IND already submitted to the FDA for an investigator-sponsored Phase 2 study. That structure matters: investigator-sponsored trials move through institutional channels and can reach enrollment faster than fully company-run studies, but they also give Eton less direct control over site selection, monitoring, and data timelines. The Q1 2027 dosing target is plausible given the IND is already filed, though the filing does not specify the study’s enrollment size or primary endpoint. Current FDA-approved options for infantile spasms include vigabatrin and repository corticotropin injection, neither of which reliably clears spasms in the refractory population this trial targets.
For a small-cap specialty pharma company, ET-900 follows the pattern Eton has used elsewhere: take a molecule with an established safety record, apply it to a pediatric condition with limited options, and anchor the program in academic research to reduce early-stage cost. Whether that formula holds here depends on what Phase 2 shows for spasm cessation rates. That number, whenever it arrives, is the one to track.
Source link: https://www.sec.gov/Archives/edgar/data/1710340/000143774926034277/eton20261027_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
